Register Login
Register to leave comments
  • News bot Jan. 8, 2026, 12:46 p.m.

    📋 Context Therapeutics Inc. (CNTX) - Clinical Trial Update

    Filing Date: 2026-01-08

    Accepted: 2026-01-08 07:43:10

    Event Type: Clinical Trial Update

    Event Details:

    Context Therapeutics Inc. (CNTX) Announces Clinical Trial Update Context Therapeutics Inc. (CNTX) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: reflected, expressed
    • Diseases/Conditions: such are reasonable
    • Clinical Stage: clinical trial
      • anticipated in 2026

    🔬 Clinical Development Pipeline (Context Therapeutics Inc.):

    Product Type Development Stage Therapeutic Area Source
    CTIM-76 DRUG Phase PHASE1 Platinum-resistant Ovarian Cancer ClinicalTrials.gov
    CT-95 DRUG Phase PHASE1 Mesothelin-Expressing Tumors ClinicalTrials.gov
    Onapristone ER DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Palbociclib DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Letrozole DRUG Phase PHASE1 Metastatic Breast Cancer ClinicalTrials.gov
    Fulvestrant DRUG Phase PHASE2 ER-positive Breast Cancer ClinicalTrials.gov
    Onapristone DRUG Phase PHASE2 ER-positive Breast Cancer ClinicalTrials.gov
    Onapristone ER + Anastrozole DRUG Phase PHASE2 Granulosa Cell Ovarian Cancer ClinicalTrials.gov
    Elacestrant DRUG Phase PHASE1 Breast Cancer ClinicalTrials.gov
    Questionnaire Administration OTHER Phase PHASE2 Refractory Endometrial Adenocarcinoma ClinicalTrials.gov
    Quality-of-Life Assessment OTHER Phase PHASE2 Refractory Endometrial Adenocarcinoma ClinicalTrials.gov
    Anastrozole DRUG Phase PHASE2 Refractory Endometrial Adenocarcinoma ClinicalTrials.gov
    Extended-release Onapristone DRUG Phase PHASE2 Refractory Endometrial Adenocarcinoma ClinicalTrials.gov

    💼 Business Developments:

    • Partnership: Not available
    • Acquisition
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Context Therapeutics Inc.
    • CIK: 0001842952
    • Ticker Symbol: CNTX
    • Period End Date: 2026-01-08
    • Document Type: 8-K

Search

News categories